Scientific work

Doç. Dr. Seray Saray

42 publications. The source of the information is stated next to each publication.

Back to profile

  1. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Open-access full textSource: ORCID

  2. Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report

    Case Reports in Oncology, 2026

    DOI 10.1159/000551796 PMID 42257038 Open-access full textSource: ORCID

  3. Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15805-w PMID 41749167 Open-access full textSource: ORCID

  4. Analysis of prognostic factors in metastatic colon cancer

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1803902 Open-access full textSource: ORCID

  5. Do Inflammatory Indices Predict Neoadjuvant Chemotherapy Response in Hormone Receptor-positive, HER2-negative Breast Cancer?

    Namık Kemal Tıp Dergisi, 2026

    DOI 10.4274/nkmj.galenos.2025.81594 Open-access full textSource: OpenAlex

  6. Low baseline breast TLG and axillary MTV independently predict pathological complete response in HR-positive/HER2-negative breast cancer

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17192-8 Open-access full textSource: OpenAlex

  7. The ımpact of the novel tumor marker ındex (TMI) on survival and prognosis in metastatic gastric cancer

    American Journal of Cancer Research, 2026

    DOI 10.62347/jgid2940 Source: OpenAlex

  8. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001717 PMID 40162996 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  9. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251368069 PMID 40900677 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Open-access full textSource: ORCID

  11. FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16261 Source: ORCID

  12. Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?

    Revista da Associação Médica Brasileira, 2025

    DOI 10.1590/1806-9282.20250507 PMID 41124552 Open-access full textSource: ORCID

  13. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14165868 PMID 40869694 1 citation (Europe PMC) Open-access full textSource: ORCID

  14. Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16264 Open-access full textSource: OpenAlex

  15. Androgen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment

    Medicina, 2025

    DOI 10.3390/medicina61081464 PMID 40870508 Open-access full textSource: ORCID

  16. Androgen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment

    Medicina (Kaunas, Lithuania), 2025

    Source: ORCID

  17. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of clinical medicine, 2025

    Source: ORCID

  18. Case report: Drug-induced vitiligo during treatment with BRAF/MEK inhibitors in a patient with metastatic conjunctival melanoma

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025

    DOI 10.1177/10781552231189819 PMID 37499639 1 citation (Europe PMC) Source: ORCID

  19. Do Inflammatory Indices Have Prognostic Value in Metastatic Breast Cancer Patients Receiving CDK 4/6 Inhibitor Therapy?

    The Eurasian Journal of Medical Investigation, 2025

    DOI 10.14744/ejmi.2025.85675 1 citation (OpenAlex) Source: ORCID

  20. Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177Lu-PSMA-617 Radioligand Treatment

    Journal of the College of Physicians and Surgeons Pakistan, 2025

    DOI 10.29271/jcpsp.2025.10.1261 PMID 41058281 Open-access full textSource: ORCID

  21. Spectrum of BRCA1 and BRCA2 Variants in Breast Cancer Cases: A Single-Center Experience

    DergiPark (Istanbul University), 2025

    Source: OpenAlex

  22. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 citations (Europe PMC) Source: OpenAlex

  23. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-81371-5 PMID 39616250 2 citations (Europe PMC) Open-access full textSource: ORCID

  24. Screening for the Frequency of Fabry Disease in Patients Followed Up in the Nephrology Outpatient Clinic

    Turkish Journal of Nephrology, 2024

    DOI 10.5152/turkjnephrol.2024.23511 Open-access full textSource: ORCID

  25. Treatment Strategies for Glioblastoma Multiforme: A Single Center Experience

    Journal of Oncological Science, 2024

    DOI 10.37047/jos.2023-98703 1 citation (OpenAlex) Open-access full textSource: ORCID

  26. Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review

    2021

    DOI 10.21203/rs.3.rs-433514/v1 Open-access full textSource: ORCID

  27. Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review

    Sisli Etfal Hastanesi tip bulteni, 2021

    DOI 10.14744/semb.2021.66503 PMID 35317367 7 citations (Europe PMC) Open-access full textSource: ORCID

  28. Tükrük Bezi Tümörlerinde Kemoterapi

    2021

    Source: OpenAlex

  29. Opere Over Kanseri Hastalarında Preoperatif Yüksek CA125 Değerinin Postoperatif Normal Sınırlara Dönmesinin Klinik Önemi

    Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2020

    DOI 10.34087/cbusbed.743230 Source: ORCID

  30. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study].

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2020

    PMID 32521852 4 citations (Europe PMC) Source: ORCID

  31. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study].

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2020

    PMID 32521907 2 citations (Europe PMC) Source: ORCID

  32. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020

    DOI 10.1007/s00520-019-05165-6 PMID 31758325 13 citations (Europe PMC) Source: ORCID

  33. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]

    JOURNAL OF BUON, 2020

    Source: ORCID

  34. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]

    Journal of B U on, 2020

    Source: ORCID

  35. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study]

    JOURNAL OF BUON, 2020

    Source: ORCID

  36. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study]

    Journal of B U on, 2020

    Source: ORCID

  37. Prognostic value of De Ritis ratio (aspartate transaminase/alanine transaminase) in patients with non-metastatic colorectal carcinoma [izmir oncology group(IZOG) study].

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e16114 Source: ORCID

  38. The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study)

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020

    DOI 10.1007/s00520-020-05477-y PMID 32335732 20 citations (Europe PMC) Source: ORCID

  39. Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The Izmir oncology group (IZOG) study

    Annals of Medical Research, 2020

    DOI 10.5455/annalsmedres.2019.12.862 Open-access full textSource: OpenAlex

  40. Prognostic role of pretreatment de ritis and neutrophil to lymphocyte ratio in neuroendocrine carcinoma patients (Izmir oncology group study)

    Annals of Medical Research, 2020

    DOI 10.5455/annalsmedres.2020.01.057 Open-access full textSource: OpenAlex

  41. ASSESMENT OF PROVEN INVASIVE FUNGAL SINUSITIS: A ONE-YEAR ONE-CENTER EXPERIENCE

    LEUKEMIA RESEARCH, 2015

    Source: ORCID

  42. Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177Lu-PSMA-617 Radioligand Treatment

    Source: ORCID